Currently out of the existing stock ratings of Matthew Stanton, 14 are a HOLD (66.67%), 7 are a BUY (33.33%).

Matthew Stanton

Work Performance Price Targets & Ratings Chart

Analyst Matthew Stanton, currently employed at JEFFERIES, carries an average stock price target met ratio of 76% that have a potential upside of 19.97% achieved within 45 days.

Matthew Stanton’s has documented 39 price targets and ratings displayed on 4 stocks. The coverage is on Industrials, Healthcare sectors.

Most recent stock forecast was given on BLFS, BioLife Solutions at 23-Jul-2026.

Wall Street Analyst Matthew Stanton

Analyst best performing recommendations are on CYRX (CRYOPORT).
The best stock recommendation documented was for CYRX (CRYOPORT) at 8/6/2025. The price target of $8 was fulfilled within 2 days with a profit of $0.75 (8.57%) receiving and performance score of 42.86.

Average potential price target upside

AZTA Azenta CYRX Cryoport RGEN Repligen BLFS BioLife Solutions

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 07-May-2021

$37

$0.5 (1.37%)

$37

1 months 16 days ago
(14-Sep-2026)

9/31 (29.03%)

$4.96 (15.48%)

133

Buy Since 05-Feb-2026

$35

$-1.5 (-4.11%)

$35

2 months 24 days ago
(06-Aug-2026)

11/14 (78.57%)

$4.26 (13.86%)

90

Buy Since 04-Feb-2026

$30

$-6.5 (-17.81%)

$40

5 months 24 days ago
(06-May-2026)

4/5 (80%)

$11.62 (63.22%)

91

Hold Since 27-Feb-2025

$30

$-6.5 (-17.81%)

$39

8 months 26 days ago
(04-Feb-2026)

3/4 (75%)

$1.51 (5.30%)

20

Buy Since 25-Nov-2025

$45

$19.5 (76.47%)

$35

11 months 4 days ago
(25-Nov-2025)

1/2 (50%)

$6.9 (18.11%)

110

Show more analysts

Please expand the browser size to see the chart

Which stock is Matthew Stanton most bullish on?

Potential upside of $-6.5 has been obtained for AZTA (AZENTA)

Which stock is Matthew Stanton most reserved on?

Potential downside of -$42.69 has been obtained for RGEN (REPLIGEN)

What Year was the first public recommendation made by Matthew Stanton?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?